Form 4 for LQDA Liquidia Corp
Accepted 2022-04-20 00:00:00 ET · period of report 2022-03-31 · accession 0001104659-22-047869 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-04-20 | 2022-03-31 | LQDA | JEFFS ROGER | CEO, Dir | A - Grant | $0.00 | +154.2K | 1.54M | +11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | A | A | 154,167 | $0.00 | 1,541,667 | I See footnote | — | — | (F2) The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. |